Alnylam Pharmaceuticals has published data on the use of combinations of novel lipid materials to systemically deliver RNAi therapeutics.
The work was conducted by Alnylam researchers in collaboration with scientists at the Massachusetts Institute of Technology (GSN 5/10/2007), and appeared in Molecular Therapy.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.
In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.
The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.
The NIH has issued a preliminary guidance for newborn dried blood spot research.